EU Authorised Representative Services & CE Marking

An EU Authorised Representative acts on behalf of a non-EU medical device manufacturer for specific regulatory obligations under EU MDR. This can include maintaining required documentation availability, supporting communications with competent authorities, and helping ensure the manufacturer meets ongoing compliance responsibilities tied to CE-marked products placed on the EU market.

CE marking support typically includes device classification, conformity assessment route selection, EU MDR regulatory strategy, technical documentation review or authoring, GSPR checklist support, risk management alignment, labeling review, clinical evidence planning, and preparation for Notified Body engagement. The goal is to create a complete, defensible compliance package that supports lawful EU market access.

The timeline depends on device class, documentation maturity, clinical evidence strength, and Notified Body availability. Lower-risk devices with strong existing files may move faster, while higher-risk devices often require more extensive remediation, clinical work, and review cycles. A readiness assessment early in the process helps identify gaps, set realistic milestones, and avoid preventable delays.

Yes, manufacturers should have well-structured technical documentation substantially prepared before formal Notified Body engagement. Reviewers expect complete and traceable evidence covering device description, GSPRs, risk management, verification and validation, clinical evaluation, labeling, and post-market planning. Incomplete files often trigger deficiencies, extra review rounds, and longer approval timelines.

Yes. Transition support typically includes gap assessment against EU MDR requirements, remediation planning, technical file upgrades, CER and PMCF strengthening, labeling updates, and alignment of post-market systems. Because EU MDR expectations are broader and more rigorous than legacy MDD requirements, structured transition planning is essential to maintain market continuity and reduce compliance risk.

A readiness review commonly covers classification rationale, technical documentation, GSPR checklist, risk management file, clinical evaluation materials, verification and validation evidence, labeling and IFU, quality system alignment, and post-market surveillance records. The review checks completeness, consistency, traceability, and whether the documentation is organized to withstand Notified Body scrutiny.

Yes. Elexes supports clinical evidence strategy, CER authoring and review, PMCF adequacy assessment, and alignment between clinical evidence, risk management, and GSPR compliance. This is especially important under EU MDR, where clinical justification is heavily scrutinized and weak evidence packages can delay CE marking or create major remediation burdens.

Yes. Ongoing support can include change impact assessments, complaint and PMS governance, documentation updates, labeling reviews, regulatory correspondence support, and broader RAQA operational assistance. Post-market compliance is a continuing obligation under EU MDR, so maintaining documentation and surveillance systems after certification is critical for long-term market access.